Table 6 Literature overview SABR, mixed populations (tp = time point, * = only NSCLC stage I, -: not stated)
Author year | N localisation | BED2* (BED10)** | OS (tp) | PFS (tp) | LC (tp) |
|---|---|---|---|---|---|
Wulf et al. [22] | 51 lung/liver | 50 Gy BED2 | - | - | 76% (1 y) 61-76% (2 y) |
Hara et al. [23] | 59 lung | 50-125 Gy BED2 | 77% (1 y) 41% (2 y) | - | 93% (1 y) 78% (2 y) |
Yoon et al. [24] | 101 lung | 50-88 Gy BED2 | 51% (2 y)* | 81% (2 y) | 82% (2 y) |
Milano et al. [25] | 293 Oligometastases | 31-72 Gy BED2 | - | - | 77% (2 y) 73% (4 y) |
Norihisa et al. [26] | 34 oligometastases | ~75 Gy BED2 | 84% (2 y) | 35% (2 y) | 90% (2 y) |
Salazar et al. [27] | 109 NSCLC I-IV + oligometastases | 120 Gy BED2 | 81% (2 y)* 48% (5 y)* | 63% | 82% |
Rusthoven et al. [28] | 63 lung | 104-150 Gy BED2 | 39% (2 y) | 37% | 100% (1 y) 96% (2 y) |
McCammon et al. [5] | 246 lung/liver | 150 Gy BED2 | - | - | 89% (>54 Gy, 3 yr) |
Bradley et al. [12] | 91 NSCLC I/II | 71-126 Gy BED2 | 58% (3 y) | 71% (3 y) | 86% (2 y) |
Duncker-Rohr et al. [29] | 45 lung (NSCLC and metastases) | 49.5-70.3 Gy BED2 | 52,7% (2 y) | - | 80,5 (2 y) |
Inoe et al. [30] | Lung metastases | 106 Gy BED10 (30-168 Gy range) | 47% (2 y) 32% (3 y) | 40% (2 y) 32% (3 y) | 80% (2 and 3 y) |
Inoe et al. [31] | 109 NSCLC I | 66 Gy BED2 | 64% (5 y) | 10% (5 y), intrathoracal progression | 78% (5 y) |
Verstegen et al. [32], SABR arm | 64 NSCLC I-II | >100 Gy BED10 | 91.8% (1 y) 79.6% (3 y) | 91.6% (1 y) 85.2% (3 y) | 96.8% (1 y) 93.3% (3 y) |
Kim et al. [33] | 16 NSCLC I | 88 Gy BED2 96 Gy BED2 | 87.5% (1.5 y) | 85.2% (1.5 y) | 91% (1.5 y) |
Shioyama et al. [34] | 8 SCLC stage I | 88 Gy BED2 | 72% (3 y) | 71% (3 y) | 100% (3 y) |
Grills et al. [35] | 505 NSCLC I-IIB | 132 Gy BED10 | 60% (2 y) | 80% (2 y) 79% (3 y), distant metastases | 94% (2 y) |